Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.

Ribas A, Milhem MM, Hoimes CJ, Amin A, Lao CD, Conry RM, Hunt JP, Daniels GA, Almubarak M, Shaheen M, Medina T, Barve M, Bishnoi S, Abdi E, Chisamore MJ, Guiducci C, Gomez-Romo J, Candia A, Gamelin E, Coffman RL, Janssen RS, Long GV

Open source

DOI: 10.1158/1078-0432.ccr-25-0987
Published: 2025 Oct 1
Container: Clinical cancer research : an official journal of the American Association for Cancer Research
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-0987,
  title = {Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.},
  author = {Ribas A and Milhem MM and Hoimes CJ and Amin A and Lao CD and Conry RM and Hunt JP and Daniels GA and Almubarak M and Shaheen M and Medina T and Barve M and Bishnoi S and Abdi E and Chisamore MJ and Guiducci C and Gomez-Romo J and Candia A and Gamelin E and Coffman RL and Janssen RS and Long GV},
  year = {2025},
  journal = {Clinical cancer research : an official journal of the American Association for Cancer Research},
  doi = {10.1158/1078-0432.ccr-25-0987},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-0987}
}

RIS

TY  - JOUR
TI  - Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.
AU  - Ribas A
AU  - Milhem MM
AU  - Hoimes CJ
AU  - Amin A
AU  - Lao CD
AU  - Conry RM
AU  - Hunt JP
AU  - Daniels GA
AU  - Almubarak M
AU  - Shaheen M
AU  - Medina T
AU  - Barve M
AU  - Bishnoi S
AU  - Abdi E
AU  - Chisamore MJ
AU  - Guiducci C
AU  - Gomez-Romo J
AU  - Candia A
AU  - Gamelin E
AU  - Coffman RL
AU  - Janssen RS
AU  - Long GV
PY  - 2025
JO  - Clinical cancer research : an official journal of the American Association for Cancer Research
DO  - 10.1158/1078-0432.ccr-25-0987
UR  - https://doi.org/10.1158/1078-0432.ccr-25-0987
ER  -

APA

A, R., MM, M., CJ, H., A, A., CD, L., RM, C., JP, H., GA, D., M, A., M, S., T, M., M, B., S, B., E, A., MJ, C., C, G., J, G., A, C., E, G., RL, C., RS, J., & GV, L. (2025). Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti-PD-1 Treatment-Naïve Advanced Melanoma.. Clinical cancer research : an official journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.ccr-25-0987

Source records

pubmed · retrieved 2026-09-26T09:48:19.420Z